IFNA1 and neoplasm: Continuous IFNα therapy also promotes long-term antitumor immunity in cured mice and protection from secondary tumor challenge, by stimulating LSECs to efficiently cross-prime tumor antigens to naïve CD8+ T cells (Figure 7F).